Equity Profile

PAHC

Phibro Animal Health Corporation

Health CarePharmaceuticals$1.4B

Aug26Wed

Pre-Earnings Brief

UpcomingQ4-2026After Close5:00 PM EDT

Company Snapshot

Phibro Animal Health Corporation (PAHC) operates in the health care sector, focusing on pharmaceuticals for animal health. The company plays a crucial role in providing solutions for livestock and poultry, which is increasingly important as global food demand rises.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company managed costs and revenue.

$0.80

Revenue Growth

Revenue growth is vital to assess the company's ability to expand its market share and product offerings.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PAHC Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+23.89%

Avg Stock Reaction

+0.37%

Last Quarter Recap

In Q3-2026, Phibro reported an EPS of $0.76, surpassing estimates by 5.85%. The stock reacted positively, gaining 4.02% the next day.

Management Promises & Guidance

Continued focus on expanding product lines.
Commitment to improving operational efficiencies.
Plans to enhance market penetration in emerging markets.

Expectations

Wall Street Expectations

Overall, expectations are cautiously optimistic as Phibro has consistently beaten EPS estimates in recent quarters. Investors are looking for continued growth in profitability and revenue.

Bull Case

If Phibro can deliver strong EPS and show signs of revenue growth, it could lead to a significant stock price increase, reinforcing investor confidence.

Bear Case

On the other hand, if the company fails to meet EPS expectations or shows signs of declining margins, it could lead to a sell-off as investors reassess their outlook.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.80

EPS is a key indicator of profitability and will show how well the company managed costs and revenue.

Revenue Growth

N/A

Revenue growth is vital to assess the company's ability to expand its market share and product offerings.

Gross Margin

N/A

Gross margin indicates the efficiency of production and pricing strategy, which is critical for profitability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to the expected $0.80?

Given Phibro's history of beating EPS estimates, this will be a key indicator of ongoing financial health.

What insights can management provide regarding revenue growth and market expansion?

Investors will closely watch for any guidance on revenue trends, especially in emerging markets, as it could significantly impact future performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating Phibro's ability to expand its product lines and penetrate new markets, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

Phibro has consistently beaten EPS estimates, indicating strong operational management.

Options pricing suggests a significant move, reflecting heightened investor interest and potential volatility.

The company's focus on emerging markets may not be fully appreciated by analysts.

Key Risk

If revenue growth exceeds expectations, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Phibro can maintain its growth trajectory in a competitive market.

Bull Confirmed If

An EPS of $0.85 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $0.75 would support the bear case, suggesting potential issues with profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±22.04%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±22.0% while PAHC has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

100.6%

Calls (100)P/C Ratio: 0.14Puts (600)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Phibro beats expectations, history suggests the stock could rise by around 0.37% on the next trading day, confirming positive momentum.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may react neutrally as investors digest the information.

Miss

If the company misses EPS expectations, history suggests a potential drop of around 2.28%, leading to a reassessment of growth prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on cost management and operational efficiencies.
3Insights into market trends and competitive landscape in animal health.
4Any guidance on revenue expectations for the upcoming quarters.
5Details on geographic expansion plans, particularly in emerging markets.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Sandisk Corporation

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company managed costs and revenue.

$0.80

Revenue Growth

Revenue growth is vital to assess the company's ability to expand its market share and product offerings.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PAHC Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+23.89%

Avg Stock Reaction

+0.37%

Last Quarter Recap

In Q3-2026, Phibro reported an EPS of $0.76, surpassing estimates by 5.85%. The stock reacted positively, gaining 4.02% the next day.

Management Promises & Guidance

Continued focus on expanding product lines.
Commitment to improving operational efficiencies.
Plans to enhance market penetration in emerging markets.

Expectations

Wall Street Expectations

Overall, expectations are cautiously optimistic as Phibro has consistently beaten EPS estimates in recent quarters. Investors are looking for continued growth in profitability and revenue.

Bull Case

If Phibro can deliver strong EPS and show signs of revenue growth, it could lead to a significant stock price increase, reinforcing investor confidence.

Bear Case

On the other hand, if the company fails to meet EPS expectations or shows signs of declining margins, it could lead to a sell-off as investors reassess their outlook.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.80

EPS is a key indicator of profitability and will show how well the company managed costs and revenue.

Revenue Growth

N/A

Revenue growth is vital to assess the company's ability to expand its market share and product offerings.

Gross Margin

N/A

Gross margin indicates the efficiency of production and pricing strategy, which is critical for profitability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to the expected $0.80?

Given Phibro's history of beating EPS estimates, this will be a key indicator of ongoing financial health.

What insights can management provide regarding revenue growth and market expansion?

Investors will closely watch for any guidance on revenue trends, especially in emerging markets, as it could significantly impact future performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating Phibro's ability to expand its product lines and penetrate new markets, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

Phibro has consistently beaten EPS estimates, indicating strong operational management.

Options pricing suggests a significant move, reflecting heightened investor interest and potential volatility.

The company's focus on emerging markets may not be fully appreciated by analysts.

Key Risk

If revenue growth exceeds expectations, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Phibro can maintain its growth trajectory in a competitive market.

Bull Confirmed If

An EPS of $0.85 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $0.75 would support the bear case, suggesting potential issues with profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±22.04%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±22.0% while PAHC has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

100.6%

Calls (100)P/C Ratio: 0.14Puts (600)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Phibro beats expectations, history suggests the stock could rise by around 0.37% on the next trading day, confirming positive momentum.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may react neutrally as investors digest the information.

Miss

If the company misses EPS expectations, history suggests a potential drop of around 2.28%, leading to a reassessment of growth prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on cost management and operational efficiencies.
3Insights into market trends and competitive landscape in animal health.
4Any guidance on revenue expectations for the upcoming quarters.
5Details on geographic expansion plans, particularly in emerging markets.